Quality Of Life in Prostate Cancer Patients Initiating Triptorelin (QOCPIT)
QOCPIT (Quality Of Life in Prostate Cancer Patients Initiating Triptorelin): A Prospective Observational Study to Evaluate Baseline Factors That Stabilize or Improve Health-related Quality of Life.
Prostate cancer and its treatment, particularly androgen deprivation therapy (ADT) may affect different aspects of a person's quality of life, including physical well-being and daily activities.
The purpose of this study is to evaluate baseline factors that stabilize or improve quality of life in patients with prostate cancer who are initiating triptorelin treatment as ADT, in routine clinical practice.
Participants in this study will be patients with prostate cancer whose treating physician has decided to initiate treatment with triptorelin.
This is an observational study. No treatment will be assigned as part of the study, and all medical decisions will be made by the treating physician according to routine clinical practice.
Participants will be followed for approximately 6 months. Information collected during the study may include demographics and medical characteristics, prostate cancer and treatments characteristics, physical activity, supportive care and quality of life. Questionnaires about quality of life and physical activity will be completed by participants at the start of the study and again approximately 6 months later. Information on adverse events occurring during the study will also be collected.
調査の概要
状態
状態
条件
条件
研究の種類
研究の種類
入学 (推定)
入学
連絡先と場所
研究連絡先
研究連絡先
- 名前:Ipsen Clinical Study Enquiries
- 電話番号:See email
- メール:clinical.trials@ipsen.com
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Adult males with prostate cancer initiating triptorelin treatment in routine clinical practice and meeting the study eligibility criteria.
説明
Inclusion Criteria:
Patients are eligible to be included in the study only if all the following criteria apply:
- Males ≥18 years old.
- Patient with histologically confirmed PCa.
- Patient eligible to start triptorelin in its labelled indication for at least 6 months and for whom the decision to start triptorelin was made voluntarily by the physician as part of routine medical practice, prior to the inclusion in the study.
- Patient able to understand and complete study-related questionnaires.
- Patient having been informed and not opposed to participating in the study.
- Patient covered by healthcare insurance.
Exclusion Criteria
Patients will not be included in the study if they meet any of the following criteria:
- Patient currently participating in any interventional clinical trial.
- Patient who received a hormonal treatment during the last 6 months before inclusion (or hormonal treatment whose duration of action may impact the 6 months before inclusion).
- Patient under tutorship or curatorship; patients under safeguard of justice or deprived of his liberty by an administrative or court decision.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Identification of baseline factors including: demographic, clinical, disease and treatment factors, associated with stabilization (change:]-10; 10[) or improvement (change ≥10) of Functional Assessment of Cancer Therapy-Prostate (FACT-P) total score
時間枠:At 6 months
|
At 6 months
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Participants' baseline demographic characteristics
時間枠:At baseline
|
Including:
|
At baseline
|
|
Participants' clinical characteristics at baseline
時間枠:At baseline
|
Including:
|
At baseline
|
|
Prostate cancer characteristics at diagnosis and baseline
時間枠:At baseline
|
Including:
|
At baseline
|
|
Participants symptoms at baseline
時間枠:At baseline
|
At baseline
|
|
|
Participants' PCa treatment patterns at baseline
時間枠:At baseline
|
|
At baseline
|
|
Participants' healthcare pathway/supportive care done or planned
時間枠:At baseline
|
Including:
|
At baseline
|
|
Evolution of PCa at 6-month follow-up according to investigator's opinion
時間枠:At 6 months
|
Evolution of PCa at 6-month follow-up according to investigator's opinion: control / stable / progression. |
At 6 months
|
|
Symptoms and biological characteristics at 6 months
時間枠:At 6 months
|
At 6 months
|
|
|
Participant's level of physical activity, using International Physical Activity Questionnaire (IPAQ) questionnaire
時間枠:At 6 months
|
The International Physical Activity Questionnaire (IPAQ) is a participant-reported questionnaire used to assess physical activity level. Higher scores indicate higher levels of physical activity. |
At 6 months
|
|
Participants' Quality Of life (QoL)
時間枠:At baseline and at 6 months
|
|
At baseline and at 6 months
|
|
Participants' PCa treatment patterns at 6 months
時間枠:At baseline and at 6 months
|
|
At baseline and at 6 months
|
|
Participants' healthcare pathway/supportive care at 6 months
時間枠:At 6 months
|
• Participant's healthcare pathway/type of supportive care in case of changes. |
At 6 months
|
|
Identification of factors associated with participant's quality of life
時間枠:At 6 months
|
• Identification of baseline factors, including demographic, clinical, disease and treatment factors, associated with stabilization (change: ]-3;3[) or improvement (change ≥3) of Physical Well-Being (PWB) and Prostate Cancer Specific (PCS) sub-scores of FACT-P at 6 months after inclusion, using a logistic model. |
At 6 months
|
|
Percentage of participants with adverse events
時間枠:From enrollment to Month 6
|
An adverse event (AE) is any untoward medical occurrence in a participant. The percentage of participants experiencing at least one adverse event, including cardiovascular events occurring after initiation of triptorelin treatment, will be assessed during study follow-up. |
From enrollment to Month 6
|
協力者と研究者
捜査官
捜査官
- スタディディレクター:Ipsen Medical Director、Ipsen
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- CLIN-52014-030
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
IPD 共有時間枠
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
IPD 共有アクセス基準
Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。